[Role of dopaminergic agonists]

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease treatment strategies have evolved over two decades.
• Initial studies investigated dopamine agonists versus levodopa for early Parkinson's disease management.
• Concerns regarding methodological limitations in early trials prompted further investigation.

Framework:

• Recent large-scale, prospective, randomized, double-blind, 5-year trials compared newer dopamine agonists (cabergoline, ropinirole) against levodopa.
• These trials aimed to confirm or refute the benefits of early dopamine agonist use on long-term outcomes.

Implementation:

• Patients received either initial dopamine agonist therapy or initial levodopa therapy.
• Dopamine agonists were used alone or supplemented with low-dose levodopa.
• Treatment efficacy and the occurrence of motor complications were monitored over five years.

Implications:

• Early initiation of dopamine agonists significantly reduces the risk of developing motor complications (dyskinesia, fluctuations) in Parkinson's disease.
• This strategy provides effective symptom control without a substantial increase in adverse dopaminergic events, particularly in patients under 70.
• Findings support the use of dopamine agonists as a preferred initial therapy to improve long-term patient outcomes in Parkinson's disease.